Abstract
Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Current Pharmaceutical Design
Title:Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review
Volume: 23 Issue: 9
Author(s): Dimitrios A. Vrachatis*, Georgios Giannopoulos, Charalambos Kossyvakis, Vasiliki Panagopoulou, Manolis Vavuranakis, Theodore G. Papaioannou, Stamatina Pagoni, Vlasios N. Pyrgakis, Michael W. Cleman and Spyridon G. Deftereos
Affiliation:
- Department of Cardiology, “G. Gennimatas” General Hospital of Athens, 154 Mesogion ave., 115 27, Athens,Greece
Keywords: Radiofrequency, cryoablation, VKA, NOAC, warfarin, dabigatran, rivaroxaban, apixaban.
Abstract: Catheter ablation for rhythm control in atrial fibrillation has been recognized as an established treatment. Patients with atrial fibrillation suffer from an increased risk of thromboembolic events. Long-term stroke risk and mortality have been shown to be reduced after catheter ablation, still the procedure per se is associated with an additive peri-procedural thromboembolic risk. Maintenance of the thrombotic - bleeding equilibrium in such patients during interventional procedures is compelling. Lack of data from randomized studies along with the recent introduction of novel oral anticoagulants in clinical practice has resulted in a wide variance of antithrombotic treatment approaches. Procedural interruption of anticoagulants, switching of anticoagulation scheme (i.e. from novel oral anticoagulants to vitamin K antagonists), bridging with heparin, timing of re-initiation of therapy and/or utilization of novel oral anticoagulants have all been points of dispute. In the present review we present the available data regarding optimal peri-procedural anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation.
Export Options
About this article
Cite this article as:
Vrachatis A. Dimitrios*, Giannopoulos Georgios, Kossyvakis Charalambos, Panagopoulou Vasiliki, Vavuranakis Manolis, Papaioannou G. Theodore, Pagoni Stamatina, Pyrgakis N. Vlasios, Cleman W. Michael and Deftereos G. Spyridon, Peri-procedural Anticoagulation in Catheter Ablation for Atrial Fibrillation: A Review, Current Pharmaceutical Design 2017; 23 (9) . https://dx.doi.org/10.2174/1381612822666161205115101
DOI https://dx.doi.org/10.2174/1381612822666161205115101 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity
Current Vascular Pharmacology Autologous Cell Therapy for Vascular Regeneration: The Role of Proangiogenic Cells
Current Medicinal Chemistry <i>Withania somnifera</i> in Neurological Disorders: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems
Current Drug Metabolism Recent Innovations in Off-Road Intelligent Vehicles: In-Field Automatic Navigation
Recent Patents on Mechanical Engineering High Throughput Screening for Neurodegeneration and Complex Disease Phenotypes
Combinatorial Chemistry & High Throughput Screening Crosstalk Between the Angiotensin and Endothelin-System in the Cerebrovasculature
Current Neurovascular Research Vascular Calcification Revisited: A New Perspective for Phosphate Transport
Current Cardiology Reviews Impact of Guidelines on Hypertension Control in the Elderly
Current Pharmaceutical Design New Targets for Treating the Underlying Pathophysiology and Nonmotor Aspects of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Development of Thiadiazole as an Antidiabetic Agent- A Review
Mini-Reviews in Medicinal Chemistry High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 in Predicting Recurrence and Severity of Stenosis in Symptomatic Intracranial Atherosclerotic Disease
Current Proteomics Carbonic Anhydrase Inhibition: Insight into Non-COX-2 Pharmacological Effect of some Coxibs
Current Pharmaceutical Design Oral Anticoagulation in Atrial Fibrillation
Cardiovascular & Hematological Agents in Medicinal Chemistry Longevity Pathways: HSF1 and FoxO Pathways, a New Therapeutic Target to Prevent Age-Related Diseases
Current Aging Science Chronic Kidney Disease and Sleeping Disordered Breathing (SDB)
Current Hypertension Reviews HGF-Antagonists: Structure, Activities, and Anti-cancer Approach
Current Signal Transduction Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry The Clinical Utility of Bivalirudin in Patients with Coronary Artery Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Global Life-Long Health Benefits of Repression of Hypothalamic NPY System by Central Leptin Gene Therapy
Current Topics in Medicinal Chemistry